Screening for urologic malignancies in primary care: Pros, cons, and recommendations

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.

Andrew J. Stephenson, MD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Louis Kuritzky, MD
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL

Steven C. Campbell, MD, PhD
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Correspondence: Steven C. Campbell, MD, PhD, Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195; campbes3@ccf.org

Drs. Stephenson and Campbell reported that they have no financial relationships that pose a potential conflict of interest with this article.

Dr. Kuritzky reported that he has received honoraria from Pfizer, Eli Lilly, ICOS, Bayer, and GlaxoSmithKline for teaching/speaking.